Cargando…
USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
BACKGROUND AND AIMS: Patients with advanced liver fibrosis owing to chronic hepatitis C virus genotype 1 represent a difficult-to-treat group even if a protease inhibitor is added to pegylated interferon alpha and ribavirin. Therefore, only patients with a high chance of cure should be treated with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687952/ https://www.ncbi.nlm.nih.gov/pubmed/26719699 http://dx.doi.org/10.2147/TCRM.S94010 |
_version_ | 1782406695923744768 |
---|---|
author | Frankova, Sona Jirsa, Milan Merta, Dusan Neroldova, Magdalena Urbanek, Petr Senkerikova, Renata Spicak, Julius Sperl, Jan |
author_facet | Frankova, Sona Jirsa, Milan Merta, Dusan Neroldova, Magdalena Urbanek, Petr Senkerikova, Renata Spicak, Julius Sperl, Jan |
author_sort | Frankova, Sona |
collection | PubMed |
description | BACKGROUND AND AIMS: Patients with advanced liver fibrosis owing to chronic hepatitis C virus genotype 1 represent a difficult-to-treat group even if a protease inhibitor is added to pegylated interferon alpha and ribavirin. Therefore, only patients with a high chance of cure should be treated with interferon-based treatment. PATIENTS AND METHODS: Expression of IFNG, IFNLR1, and interferon-sensitive genes CXCL9, IFI16, IFI27, ISG15, and USP18 in peripheral blood mononuclear cells was assessed before and during the initial 12 weeks of treatment. The studied group consisted of 26 treatment-experienced patients of average age of 50 years with advanced liver fibrosis compared to seven healthy volunteers. Fourteen patients were treated with pegylated interferon alpha 2b, ribavirin, and boceprevir and 12 patients with telaprevir. The overall sustained virological response (SVR) rate was 69% (18/26). RESULTS: A significant difference in the initial expression (median, interquartile range [IQR]) of CXCL9 2.9×, IQR: 1.7–12.4 vs 1.2×, IQR: 0.5–1.8; (P=0.01) IFNG 7.3×, IQR: 1.7–32.6 vs 0.7×, IQR: 0.4–1.3; P=0.002 and USP18 3.7×, IQR: 2.1–7.7 vs 1.4×, IQR: 0.9–1.6; (P=0.03) was found between the SVR and non-SVR groups. Expression of all analyzed genes was progressively increasing during the first 12 weeks of therapy, but a significant difference between SVR and non-SVR group was found only in USP18 expression at week 12 (P=0.001). Initial expression of four genes predicted SVR in univariate analysis (CXCL9 [OR: 12.00, 95% CI: 1.21–118.89], IFI27 [OR: 12.00, 95% CI: 1.21–118.89], IFNG [OR: 10.50, 95% CI: 1.50–73.67], USP18 [OR: 21.00, 95% CI: 2.05–215.18]). In multivariate analysis, only the initial expression of USP18 was identified as a predictor of SVR (P=0.047). CONCLUSION: Initial expression of USP18 and the course of its activation could be a reliable predictor of SVR achievement. |
format | Online Article Text |
id | pubmed-4687952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46879522015-12-30 USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study Frankova, Sona Jirsa, Milan Merta, Dusan Neroldova, Magdalena Urbanek, Petr Senkerikova, Renata Spicak, Julius Sperl, Jan Ther Clin Risk Manag Original Research BACKGROUND AND AIMS: Patients with advanced liver fibrosis owing to chronic hepatitis C virus genotype 1 represent a difficult-to-treat group even if a protease inhibitor is added to pegylated interferon alpha and ribavirin. Therefore, only patients with a high chance of cure should be treated with interferon-based treatment. PATIENTS AND METHODS: Expression of IFNG, IFNLR1, and interferon-sensitive genes CXCL9, IFI16, IFI27, ISG15, and USP18 in peripheral blood mononuclear cells was assessed before and during the initial 12 weeks of treatment. The studied group consisted of 26 treatment-experienced patients of average age of 50 years with advanced liver fibrosis compared to seven healthy volunteers. Fourteen patients were treated with pegylated interferon alpha 2b, ribavirin, and boceprevir and 12 patients with telaprevir. The overall sustained virological response (SVR) rate was 69% (18/26). RESULTS: A significant difference in the initial expression (median, interquartile range [IQR]) of CXCL9 2.9×, IQR: 1.7–12.4 vs 1.2×, IQR: 0.5–1.8; (P=0.01) IFNG 7.3×, IQR: 1.7–32.6 vs 0.7×, IQR: 0.4–1.3; P=0.002 and USP18 3.7×, IQR: 2.1–7.7 vs 1.4×, IQR: 0.9–1.6; (P=0.03) was found between the SVR and non-SVR groups. Expression of all analyzed genes was progressively increasing during the first 12 weeks of therapy, but a significant difference between SVR and non-SVR group was found only in USP18 expression at week 12 (P=0.001). Initial expression of four genes predicted SVR in univariate analysis (CXCL9 [OR: 12.00, 95% CI: 1.21–118.89], IFI27 [OR: 12.00, 95% CI: 1.21–118.89], IFNG [OR: 10.50, 95% CI: 1.50–73.67], USP18 [OR: 21.00, 95% CI: 2.05–215.18]). In multivariate analysis, only the initial expression of USP18 was identified as a predictor of SVR (P=0.047). CONCLUSION: Initial expression of USP18 and the course of its activation could be a reliable predictor of SVR achievement. Dove Medical Press 2015-12-17 /pmc/articles/PMC4687952/ /pubmed/26719699 http://dx.doi.org/10.2147/TCRM.S94010 Text en © 2015 Frankova et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Frankova, Sona Jirsa, Milan Merta, Dusan Neroldova, Magdalena Urbanek, Petr Senkerikova, Renata Spicak, Julius Sperl, Jan USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study |
title | USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study |
title_full | USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study |
title_fullStr | USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study |
title_full_unstemmed | USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study |
title_short | USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study |
title_sort | usp18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis c, genotype 1: a pilot study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687952/ https://www.ncbi.nlm.nih.gov/pubmed/26719699 http://dx.doi.org/10.2147/TCRM.S94010 |
work_keys_str_mv | AT frankovasona usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy AT jirsamilan usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy AT mertadusan usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy AT neroldovamagdalena usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy AT urbanekpetr usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy AT senkerikovarenata usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy AT spicakjulius usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy AT sperljan usp18downregulationinperipheralbloodmononuclearcellspredictsnonresponsetointerferonbasedtripletherapyinpatientswithchronichepatitiscgenotype1apilotstudy |